Alison Hwong1, Kara Wang1, Stephen Bent1, Christina Mangurian1. 1. Department of Psychiatry, University of California, San Francisco (UCSF), and UCSF Weill Institute for Neurosciences, San Francisco (Hwong, Mangurian); UCSF School of Medicine, San Francisco (Wang); Department of Medicine, UCSF (Bent).
Abstract
OBJECTIVE: Women with schizophrenia appear to receive breast cancer diagnoses at later stages of the disease compared with the general population. To study this disparity, this report reviewed and quantified the differences in rates of mammography screening for women with schizophrenia and other psychotic disorders compared with the general population. METHODS: A systematic literature search was conducted in PubMed, Embase, Web of Science, and PsycINFO databases. Each database was searched from inception to September 14, 2018. The search strategy included search terms for breast cancer, mammography, schizophrenia, and psychosis. Two reviewers independently screened and evaluated eligible studies. The main outcome measure was the rate of mammography screening among women with schizophrenia and psychotic disorders versus a comparable population of women without these diagnoses. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used for abstracting data, and the Newcastle-Ottawa Scale was used for assessing data quality. A meta-analysis with a random-effects model was performed. RESULTS: From a total of 304 abstracts reviewed, 11 studies met the inclusion criteria, representing 25,447 women with diagnoses of schizophrenia or psychosis across four countries. The meta-analysis showed that women with schizophrenia were less likely than women without schizophrenia to receive mammography screening (pooled OR=0.50, 95% confidence interval=0.38-0.64, p<0.001). In subgroup analysis, this association was not significantly affected by quality of the study. CONCLUSIONS: Women with schizophrenia and other psychotic disorders were about half as likely as the general population to receive mammography screening. Further research is needed to determine causes of this disparity.
OBJECTIVE:Women with schizophrenia appear to receive breast cancer diagnoses at later stages of the disease compared with the general population. To study this disparity, this report reviewed and quantified the differences in rates of mammography screening for women with schizophrenia and other psychotic disorders compared with the general population. METHODS: A systematic literature search was conducted in PubMed, Embase, Web of Science, and PsycINFO databases. Each database was searched from inception to September 14, 2018. The search strategy included search terms for breast cancer, mammography, schizophrenia, and psychosis. Two reviewers independently screened and evaluated eligible studies. The main outcome measure was the rate of mammography screening among women with schizophrenia and psychotic disorders versus a comparable population of women without these diagnoses. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used for abstracting data, and the Newcastle-Ottawa Scale was used for assessing data quality. A meta-analysis with a random-effects model was performed. RESULTS: From a total of 304 abstracts reviewed, 11 studies met the inclusion criteria, representing 25,447 women with diagnoses of schizophrenia or psychosis across four countries. The meta-analysis showed that women with schizophrenia were less likely than women without schizophrenia to receive mammography screening (pooled OR=0.50, 95% confidence interval=0.38-0.64, p<0.001). In subgroup analysis, this association was not significantly affected by quality of the study. CONCLUSIONS:Women with schizophrenia and other psychotic disorders were about half as likely as the general population to receive mammography screening. Further research is needed to determine causes of this disparity.
Entities:
Keywords:
Breast cancer; Medical morbidity and mortality in psychiatric patients; mammography screening disparity; schizophrenia
Authors: Ursula Werneke; Oded Horn; Alan Maryon-Davis; Simon Wessely; Stuart Donnan; Klim McPherson Journal: J Epidemiol Community Health Date: 2006-07 Impact factor: 3.710
Authors: Melanie Thomas; Monique James; Eric Vittinghoff; Jennifer M Creasman; Dean Schillinger; Christina Mangurian Journal: Psychiatr Serv Date: 2017-09-15 Impact factor: 3.084
Authors: Maria E Garcia; Dean Schillinger; Eric Vittinghoff; Jennifer M Creasman; Penelope Knapp; John W Newcomer; Christina Mangurian Journal: Psychiatr Serv Date: 2017-03-01 Impact factor: 3.084
Authors: Kelly E Irwin; Elyse R Park; Lauren E Fields; Amy E Corveleyn; Joseph A Greer; Giselle K Perez; Catherine A Callaway; Jamie M Jacobs; Andrew A Nierenberg; Jennifer S Temel; David P Ryan; William F Pirl Journal: Oncologist Date: 2019-01-29
Authors: Tahir Rahman; John M Sahrmann; Margaret A Olsen; Katelin B Nickel; J Phillip Miller; Cynthia Ma; Richard A Grucza Journal: J Clin Psychopharmacol Date: 2022 Jan-Feb 01 Impact factor: 3.153
Authors: Matthew L Goldman; Christina Mangurian; Tom Corbeil; Melanie M Wall; Fei Tang; Morgan Haselden; Susan M Essock; Eric Frimpong; Franco Mascayano; Marleen Radigan; Matthew Schneider; Rui Wang; Lisa B Dixon; Mark Olfson; Thomas E Smith Journal: Gen Hosp Psychiatry Date: 2020-06-23 Impact factor: 3.238
Authors: Siobhan Reilly; Catherine McCabe; Natalie Marchevsky; Maria Green; Linda Davies; Natalie Ives; Humera Plappert; Jon Allard; Tim Rawcliffe; John Gibson; Michael Clark; Vanessa Pinfold; Linda Gask; Peter Huxley; Richard Byng; Max Birchwood Journal: BJPsych Open Date: 2021-02-15